Renovia is a biotech startup that Marc Beer initiated in Boston back in 2016 with the goal of developing treatments for various disorders, particular pelvic floor disorder. The series of funding performed by Marc in 2018 was able to generate more than 40 million dollars in funds to go towards new research and product development, making the road forward a little brighter in the healthcare community throughout Boston.
Pelvic floor disorder is not necessarily a life-threatening disease, but it does affect hundreds of millions of women all around the world today. This disorder is uncomfortable and even painful to live with, in most cases, which is why Marc Beer has made Renovia one of the first medical companies to focus on it.
The community has a positive outlook on Renovia as well, with many generous supporters throughout the healthcare community. Various investors have been Renovia, including Ascension Ventures, The Longwood Fund, and Perceptive Advisors. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer
In April of last year, Renovia was able to get the approval of the FDA for its first product to treat pelvic floor disorder patients known as Leva. Leva acts as a digital health system and they still have a lot of work to do in order to make it optimal for the millions of women out there dealing with pelvic floor disorder.
Marc Beer has more than two decades of experience working in the pharmaceutical and biotech industries and he is experienced in the commercialization and development of products to treat disorders. Marc has personally developed other drugs in the past to treat various conditions, such as high cholesterol. Renovia is the first attempt by Marc Beer to develop products under the backing of a company, which was the basis on which the FDA didn’t approve his former products.
Currently, Renovia ahs Leva on the market and it is still being tested and developed. At the same time, Renovia also has several other products in the works, though they are not yet ready to be approved by the FDA. With more than 200 million women around the world facing pelvic floor disorder, based on scientist estimates, Renovia could prove one of the most beneficial biotech companies on the market for women’s health in the near future.